2009 Canadian Hypertension Education Program recommendations: An annual update

Canadian Family Physician

Volumn 55, Issue 7, 2009, Pages 697-700

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLUCOSE; PROTEIN; RAMIPRIL; TELMISARTAN;

ABDOMINAL OBESITY; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CANADA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES MELLITUS; DYSLIPIDEMIA; EATING DISORDER; EDUCATION PROGRAM; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; HEART FAILURE; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; IMMOBILIZATION; KIDNEY DISEASE; LIFESTYLE MODIFICATION; LOW DRUG DOSE; PROTEIN URINE LEVEL; REVIEW; RISK REDUCTION; SMOKING;

BEHAVIOR THERAPY; BLOOD PRESSURE DETERMINATION; CANADA; DIABETES COMPLICATIONS; EDUCATION, MEDICAL, CONTINUING; EVIDENCE-BASED MEDICINE; FAMILY PRACTICE; HUMANS; HYPERTENSION; PATIENT COMPLIANCE; PRACTICE GUIDELINES AS TOPIC; PROGRAM DEVELOPMENT;

EID: 67651161996     PISSN: 0008350X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Hemmelgarn BR, Chen G, Walker R, McAlister FA, Quan H, Tu K, et al. Trends in antihypertensive drug prescriptions and physician visits in Canada between 1996 and 2006. Can J Cardiol 2008;24(6):507-512
2. World Health Organization. The world health report 2002. Reducing risks, promoting healthy life. Geneva, Switz: World Health Organization; 2002. Available from: www.who.int/whr/2002/en/index.html. Accessed 2009 Jun 3.
3. Lawes CM, Vander Hoorn S, Law MR, Elliott P, MacMahon S, Rodgers A. Blood pressure and the global burden of disease 2000. Part II: estimates of attributable burden. J Hypertens 2006;24(3):423-430
4. Campbell N. Hypertension prevention and control in Canada. J Am Soc Hypertens 2008;2(2):97-105.
5. Mohan S, Campbell NR. Hypertension management in Canada: good news, but important challenges remain. CMAJ 2008;178(11):1458-1460
6. Campbell NR, Brant R, Johansen H, Walker RL, Wielgosz A, Onysko J, et al. Increases in antihypertensive prescriptions and reductions in cardiovascular events in Canada. Hypertension 2009;53(2):128-134 Epub 2008 Dec 29.
7. Amankwah E, Campbell NR, Maxwell C, Onysko J, Quan H. Why some adult Canadians do not have blood pressure measured. J Clin Hypertens (Greenwich) 2007;9(12):944-951
8. Neutel CI, Campbell NR. Changes in lifestyle after hypertension diagnosis in Canada. Can J Cardiol 2008;24(3):199-204.
9. Campbell NR, So L, Amankwah E, Quan H, Maxwell C. Characteristics of hypertensive Canadians not receiving drug therapy. Can J Cardiol 2008;24(6):485-490
10. Leenen FH, Dumais J, McInnis NH, Turton P, Stratychuk L, Nemeth K, et al. Results of the Ontario survey on the prevalence and control of hypertension. CMAJ 2008;178(11):1441-1449
11. Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension 2001;37(4):1053-1059
12. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345(12):861-869
13. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345(12):851-860
14. Centers for Disease Control and Prevention Diabetes Cost-effectiveness Group. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA 2002;287(19):2542-2551
15. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998;351(9118):1755-1762
16. Tuomilehto J, Rastenyte D, Birkenhager WH, Thijs L, Antikainen R, Bulpitt CJ, et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med 1999;340(9):677-684
17. Turnbull F, Neal B, Algert C, Chalmers J, Chapman N, Cutler J, et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomised trials. Arch Intern Med 2005;165(12):1410-1419
18. Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002;61(3):1086-1097
19. Patel A; Advance Collaborative Group, MacMahon S, Chalmers J, Neal B, Woodward M, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007;370(9590):829-840
20. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355(9200):253-9. Erratum in: Lancet 2000;356(9232):860.
21. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317(7160):703-13. Erratum in: BMJ 1999;318(7175):29.
22. McInnis NH, Fodor G, Lum-Kwong MM, Leenen FH. Antihypertensive medication use and blood pressure control: a community-based cross-sectional survey (ON-BP). Am J Hypertens 2008;21(11):1210-1215 Epub 2008 Sep 4.
23. Taler SJ, Textor SC, Augustine JE. Resistant hypertension: comparing hemodynamic management to specialist care. Hypertension 2002;39(5):982-988
24. Moser M, Setaro JF. Clinical practice. Resistant or difficult-to-control hypertension. N Engl J Med 2006;355(4):385-392
25. Pool JL. Is it time to move to multidrug combinations? Am J Hypertens 2003;16(11 Pt 2):36S-40S.
26. Campbell NR, Khan NA, Hill MD, Tremblay ML, Kaczorowski J, McAlister FA, et al. 2009 Canadian Hypertension Education Program recommendations: the scientific summary - an annual update. Can J Cardiol 2009;25(5):271-277
27. Whelton PK, Barzilay J, Cushman WC, Davis BR, Iiamathi E, Kostis JB, et al. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2005;165(12):1401-1409
28. Agarwal R. Hypertension, hypokalemia, and thiazide-induced diabetes: a 3-way connection. Hypertension 2008;52(6):1012-1013 Epub 2008 Nov 3.
29. Franse LV, Pahor M, Di Bari M, Somes GW, Cushman WC, Applegate WB. Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the Elderly Program. Hypertension 2000;35(5):1025-1030
30. Wiklund I, Halling K, Ryden-Bergsten T, Fletcher A. Does lowering the blood pressure improve the mood? Quality-of-life results from the Hypertension Optimal Treatment (HOT) study. Blood Press 1997;6(6):357-364
31. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358(15):1547-1559 Epub 2008 Mar 31.
32. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008;372(9638):547-553
33. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008;358(18):1887-1898 Epub 2008 Mar 31.
34. Yusuf S, Diener HC, Sacco RL, Cotton D, Ounpuu S, Lawton WA, et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 2008;359(12):1225-1237 Epub 2008 Aug 27.
35. Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008;372(9644):1174-1183 Epub 2008 Aug 29.
36. Canadian Hypertension Education Program. The 2008 Canadian Hypertension Education Program recommendations: the scientific summary - an annual update. Can J Cardiol 2008;24(6):447-452
37. Ashenden R, Silagy C, Weller D. A systematic review of the effectiveness of promoting lifestyle change in general practice. Fam Pract 1997;14(2):160-176
38. Penz ED, Joffres MR, Campbell NR. Reducing dietary sodium and decreases in cardiovascular disease in Canada. Can J Cardiol 2008;24(6):497-501